News Headline Summary

Johnson & Johnson (JNJ) Q4 EPS Ex-items USD 1.19 vs. Exp. USD 1.16

- Q4 Revenue USD 17.6bln vs. Exp. USD 17.652bln
- Guidance for 2013 of USD 5.35 to USD 5.45 vs. Exp. USD 5.05 to USD 5.28

Q4 MAJOR SELLING DRUG SALES:

- Remicade Q4 sales USD 1.50bln vs. Exp. 1.50bln
- Prezista Q4 sales USD 353mln vs. Exp. USD 367.3mln
- Velcade Q4 sales USD 502mln vs. Exp USD 363.7mln

**A full run-down of activity in the larger capped US stocks who reported before the opening bell today will be available on the website once pre-market trading volumes pick-up. They will therefore be available at 1345GMT.

Reaction details:

- In pre-market trade, Co. shares are trading down 1.0%.

Print 12:45, 22 Jan 2013 - US Equities - Source: Newswires